Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.51 |
| ▸ | CHRNA10 | Q9GZZ6 | 6/20 | 0.51 |
| ▸ | CHRNA9 | Q9UGM1 | 6/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401284 | 0.92 | HDAC1 (0.56) | CHRNA7CHRNA10CHRNA9HDAC1HDAC4 | |
| SCHEMBL21490445 | 0.90 | HDAC1 (0.53) | CHRNA7CHRNA10CHRNA9HDAC1HDAC4 | |
| SCHEMBL13813038 | 0.86 | CHRNA7 (0.50) | CHRNA7CHRNA10CHRNA9HDAC1HDAC4 | |
| SCHEMBL13334112 | 0.85 | HDAC1 (0.50) | CHRNA7CHRNA10CHRNA9HDAC1HDAC4 | |
| SCHEMBL29724061 | 0.85 | HDAC1 (0.59) | CHRNA7CHRNA10CHRNA9HDAC1HDAC4 | |
| SCHEMBL21629876 | 0.85 | HDAC1 (0.59) | CHRNA7CHRNA10CHRNA9HDAC1HDAC4 | |
| Bromide SCHEMBL3310352 | 0.84 | HDAC1 (0.49) | CHRNA7CHRNA10CHRNA9HDAC1HDAC4 | |
| SCHEMBL21490440 | 0.83 | HDAC1 (0.61) | CHRNA7CHRNA10CHRNA9HDAC1HDAC4 | |
| SCHEMBL21490430 | 0.83 | HDAC1 (0.61) | CHRNA7CHRNA10CHRNA9HDAC1HDAC4 | |
| SCHEMBL13361702 | 0.83 | GGPS1 (0.46) | CHRNA7CHRNA10CHRNA9HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499518-B2 | Bis-quaternary ammonium salts as pain modulating agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160279119-A9 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2016-09-29 | — | — | US | disclosed |
| US-8178678-B2 | Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110166177-A1 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166177-A1 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | RELA, FHIT, OPRL1 | CHRNA7 448/4885CHRNA10 265/4885CHRNA9 454/4885 |
| US-20160279119-A9 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | RELA, FHIT, OPRL1 | CHRNA7 448/4885CHRNA10 265/4885CHRNA9 454/4885 |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA5, CHRNA4 | CHRNA7 7/4885CHRNA10 4/4885CHRNA9 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.